Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for cancer prevention in Li-Fraumeni syndrome (Phase IIIb randomized open-label trial)
2025-520714-63-00Phase 3Authorised
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of metformin in Li-Fraumeni syndrome (LFS), cancer and Neoplasm (2 arms), sponsored by Medizinische Hochschule Hannover. Primary endpoint: Cancer-free survival. Planned start Aug 2025; status: authorised.
02
Drugs
metformin
03
Conditions
Li-Fraumeni syndrome (LFS)cancerNeoplasm
Beyond the preview
Go deeper on 2025-520714-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520714-63-00.